Updates in the Treatment of Secondary AML After the 2024 SOHO Annual Meeting - Episode 3

Long-Term Data for CPX-351 in Secondary AML

,

James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss long-term data for CPX-351 in acute myeloid leukemia.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: The Diagnosis and Prevalence of Secondary AML
    EP. 2: Defining Intensive Chemotherapy Fitness in AML
    Now Viewing
    EP. 3: Long-Term Data for CPX-351 in Secondary AML
    EP. 4: Dose Intensity and Sequencing of Intensive Chemotherapy in Secondary AML
    EP. 5: Factors When Weighing Intensive Chemotherapy vs Other Regimens in Secondary AML
    EP. 6: Goals in the Treatment of Secondary AML
    EP. 7: The Role of Genetic Profiling in Secondary AML
    x